[en] To evaluate the value of lithium carbonate in the treatment of Graves disease (GD) with ¹³¹I, fifty eight GD patients received lithium carbonate for 15 days,the thyroid ¹³¹I uptake rates at 2, 4, 24h were measured before and after 7 days of taking lithium carbonate, and then the GD patients were treated with ¹³¹I. The patients were then follow-up visited for 2 years. The results showed that the ¹³¹I uptake rates of thyroid in GD patients at 2, 4 and 24h after taking lithium carbonate were significantly increased compared with that of before the lithium carbonate, it was increased 13.1%, 21.7% and 26% respectively. ¹³¹I uptake rates of thyroid were significantly different before and after the treatment of lithium carbonate (P<0.01). After 2 years of ¹³¹I treatment, fifty patients were curing,and the cure rate was 86.2%. The results indicate that lithium carbonate can increase thyroid ¹³¹I uptake rate in GD patients, prolong its effective half life, decrease the ¹³¹I treatment dose and extend therapeutic extent for GD patients. (authors)